Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Burden of providing drug listing information "could be greatly reduced if FDA were to eliminate the requirement to send a representative label and/or carton" with listing forms, OTC private labeler tells agency in Dec. 13 comments. Perrigo instead suggests representative labeling could be supplied to FDA upon request. Firm estimates its time "required to prepare a drug listing submission without representative labeling would be reduced by 75% (240 hours)." Moreover, change would reduce FDA processing time and "facilitate the feasibility of electronic submissions," Perrigo maintains
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning